{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"51.9","upperLimit":"95.7","value":"80.0"},{"groupId":"OG001","lowerLimit":"35.9","upperLimit":"99.6","value":"83.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"ORR is defined as the percentage of participants with CR or PR per investigator assessment according to the Revised Response Criteria for Malignant Lymphoma (Cheson 2014).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with an increased risk of tumor lysis syndrome (TLS) enrolled into the open-label Safety Run-in Period received concurrent ibrutinib at 560 mg once daily and venetoclax starting at 20 mg, and gradually ramped up to a target dose of 400 mg once daily over a 5-week period.","id":"OG000","title":"Safety Run-in: Increased TLS Risk at Baseline"},{"description":"Participants with an low risk of TLS enrolled into the open-label Safety Run-in Period received concurrent ibrutinib at 560 mg once daily and venetoclax starting at 20 mg, and gradually ramped up to a target dose of 400 mg once daily over a 5-week period.","id":"OG001","title":"Safety Run-in: Low TLS Risk at Baseline"}],"paramType":"NUMBER","populationDescription":"All enrolled Safety Run-in participants","reportingStatus":"POSTED","timeFrame":"For an overall median time on study of 74.78 months","title":"Overall Response Rate (ORR) (Safety Run-in)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}